[Endometrial adenocarcinoma appearing during tamoxifen therapy. Report of a clinical case].
Tamoxifen is a non-steroid estrogenic antagonist, used in post-surgical therapy of breast cancer. It interferes with endocrinous promotion of breast cancer. Tamoxifen could determine endometrial, even carcinomatous, alterations. The case of a postmenopausal patient surgically treated for breast cancer and successively treated with tamoxifen (20 mg/die), is reported. She underwent ultrasonographic and hysterosonographic endometrial evaluation and finally a hysterectomy with bilateral annessiectomy. This case seems to confirm tamoxifen possible carcinogenical effects on the endometrium.
Menada
M V
MV
Dipartimento di Ginecologia ed Ostetricia, Ospedale S. Martino, Università degli Studi, Genova.
Corticelli
A
A
Giannesi
A
A
Nicoletti
L
L
Podesta
M
M
Rissone
R
R
Fulcheri
E
E
D000230:Adenocarcinoma / Q000139:chemically induced*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D016889:Endometrial Neoplasms / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000009:adverse effects*
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen